Gilman retires amidst SEC investigation

Sidney Gilman retired as a professor of neurology from the University of Michigan Medical School. Last week, the Securities and Exchange Commission filed civil charges against Gilman alleging insider trading related to discontinued Alzheimer's disease compound bapineuzumab.

According to the SEC suit, investors made more than $276 million in profits and avoided losses due to information provided by Gilman, who was chairman of a safety monitoring committee for a Phase II trial of bapineuzumab. The SEC said it agreed to settle the charges against Gilman in exchange for his cooperation (see BioCentury Extra, Nov. 21). ...